



ATTORNEYS AT LAW



Robert Greene Sterne  
Edward J. Kessler  
Jorge A. Goldstein  
David K.S. Cornwell  
Robert W. Esmond  
Tracy-Gene G. Durkin  
Michele A. Cimbala  
Michael B. Ray  
Robert E. Sokohl  
Eric K. Steffe  
Michael Q. Lee  
Steven R. Ludwig  
John M. Covert  
Linda E. Alcorn  
Robert C. Millonig  
Lawrence B. Bugalsky  
Donald J. Featherstone  
Michael V. Messinger  
Judith U. Kim  
Timothy J. Shea, Jr.

Patrick E. Garrett  
Jeffrey T. Helvey\*  
Heidi L. Kraus  
Crystal D. Sayles  
Edward W. Yee  
Albert L. Fern\*  
Donald R. Banowitz  
Peter A. Jackman  
Molly A. McCall  
Teresa U. Medler  
Jeffrey S. Weaver  
Kendrick P. Patterson  
Vincent L. Capuano  
Albert J. Fasulo II\*  
Eldora Ellison Floyd  
W. Russell Swindell  
Thomas C. Fiala  
Brian J. Del Buono\*  
Virgil Lee Beaston\*  
Reginald D. Lucas\*

Kimberly N. Reddick  
Theodore A. Wood  
Elizabeth J. Haanes  
Bruce E. Chalker  
Joseph S. Ostroff  
Frank R. Cottingham\*  
Christine M. Lhuier  
Rae Lynn Pringaman\*  
Jane Shershenovich\*  
Lawrence J. Carroll\*  
George S. Bardmesser

**Senior Counsel**  
Samuel L. Fox  
Kenneth C. Bass III

**Registered Patent Agents**  
Karen R. Markowicz  
Andrea J. Kamage

Nancy J. Leith  
Joseph M. Conrad III  
Ann E. Summerfield  
Helena C. Carlson  
Gaby L. Longsworth  
Matthew J. Dowd  
Aaron L. Schwartz  
Angelique G. Uy  
Boris A. Matveiko  
Mary B. Tung  
Katrina Y. Pei  
Bryan L. Skelton  
Jason D. Eisenberg  
Alicia M. Choi

\*Admitted only in Maryland  
\*Admitted only in Virginia  
\*Admitted only in Texas

April 16, 2002

**WRITER'S DIRECT NUMBER:**  
(202) 371-2673

**INTERNET ADDRESS:**  
JCOVERT@SKGF.COM

**RECEIVED**

Commissioner for Patents  
Washington, D.C. 20231

APR 17 2002

Art Unit 1646

TECH CENTER 1600/2900

Re: U.S. Utility Patent Application  
Appl. No. 09/809,060; Filed: March 16, 2001  
For: **A Method for Generating Immunogens that Elicit Neutralizing Antibodies Against Fusion-Active Regions of HIV Envelope Proteins**  
Inventors: Wild *et al.*  
Our Ref: 1900.0260001/JMC/CML

Sir:

Transmitted herewith for appropriate action are the following documents:

1. Second Supplemental Information Disclosure Statement;
2. Form PTO-1449 listing four (4) cited documents (2 pages);
3. Copies of the four (4) cited documents as listed on Form PTO-1449 (AT12, AR13-AT13); and
4. One (1) return postcard.

Commissioner for Patents  
April 16, 2002  
Page 2

It is respectfully requested that the attached postcard be stamped with the date of filing of these documents, and that it be returned to our courier. In the event that extensions of time are necessary to prevent abandonment of this patent application, then such extensions of time are hereby petitioned.

Respectfully submitted,

STERNE, KESSLER, GOLDSTEIN & FOX P.L.L.C.



John M. Covert

Attorney for Applicants  
Registration No. 38,759

JMC/CML:dms  
Enclosures

SKGF\_DC1:3398.1

#5

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re application of:

Wild *et al.*

Appl. No. 09/809,060

Filed: March 16, 2001

For: **A Method for Generating  
Immunogens that Elicit Neutralizing  
Antibodies Against Fusion-Active  
Regions of HIV Envelope Proteins**

Confirmation No.

Art Unit: 1646

Examiner: *To be assigned*

Atty. Docket: 1900.0260001/JMC/CML

RECEIVED

APR 17 2002

TECH CENTER 1600/2900

**Second Supplemental Information Disclosure Statement**

Commissioner for Patents  
Washington, D.C. 20231

Sir:

Listed on accompanying Form PTO-1449 are documents that may be considered material to the examination of this application, in compliance with the duty of disclosure requirements of 37 C.F.R. §§ 1.56, 1.97 and 1.98. The numbering on this **Second Supplemental Information Disclosure Statement** is a continuation of the numbering in Applicants' **First Supplemental** Information Disclosure Statement filed on **February 26, 2002** in connection with the above-captioned application. A copy of each document is also provided.

Where the publication date of a listed document does not provide a month of publication, the year of publication of the listed document is sufficiently earlier than the effective U.S. filing date and any foreign priority date so that the month of publication is not in issue. Applicants have listed publication dates on the attached PTO-1449 based on information presently available to the undersigned. However, the listed publication dates should not be construed as an admission that the information was actually published on the date indicated.

Applicants reserve the right to establish the patentability of the claimed invention over any of the information provided herewith, and/or to prove that this information may not be prior art, and/or to prove that this information may not be enabling for the teachings purportedly offered. This statement should not be construed as a representation that a search has been made, or that information more material to the examination of the present patent application does not exist.

This Information Disclosure Statement is being filed more than three months after the U.S. filing date, but before the mailing date of a first Office Action on the merits. No statement or fee is required.

Respectfully submitted,

STERNE, KESSLER, GOLDSTEIN & FOX P.L.L.C.

  
John M. Covert  
Attorney for Applicants  
Registration No. 38,759

Date: April 16, 2002

1100 New York Avenue, N.W.  
Suite 600  
Washington, D.C. 20005-3934  
(202) 371-2600

FORM PTO-1449 SECOND SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT		ATTY. DOCKET NO. 1900.0260001	APPLICATION NO. 09/809,060
		APR 16 2002	APPLICANT Wild et al.
		FILING DATE March 16, 2001	GROUP 1646

## U.S. PATENT DOCUMENTS

EXAMINER INITIAL		DOCUMENT NUMBER	DATE	NAME	CLASS	SUB-CLASS	FILING DATE
AA							
AB							
AC							
AD							
AE							
AF							RECEIVED
AG							APR 17 2002
AH							TECH CENTER 1600/2900
AI							
AJ							
AK							

## FOREIGN PATENT DOCUMENTS

EXAMINER INITIAL		DOCUMENT NUMBER	DATE	COUNTRY	CLASS	SUB-CLASS	TRANSLATION
AL							Yes No
AM							Yes No
AN							Yes No
AO							Yes No
AP							Yes No

## OTHER (Including Author, Title, Date, Pertinent Pages, etc.)

	AT	12	Kliger, Y. and Shai Y., "Inhibition of HIV-1 Entry Before gp41 Folds Into its Fusion-active Conformation," <i>J. Mol. Biol.</i> 295:163-168, Academic Press, Ltd. (January 2000)
	AR	13	LaCasse, R.A. et al., "Fusion-Competent Vaccines: Broad Neutralization of Primary Isolates of HIV," <i>Science</i> 283:357-362, American Association for the Advancement of Science (1999)
	AS	13	Rabinstein, M., and Shin, Y-K., "A Peptide from the Heptad Repeat of Human Immunodeficiency Virus gp41 Shows both Membrane Binding and Coiled-Coil Formation," <i>Biochemistry</i> 34:13390-13397, American Chemical Society (1995)

EXAMINER	DATE CONSIDERED

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to Applicant.

		ATTY. DOCKET NO. 1900.0260001	APPLICATION NO. 09/809,060
		APPLICANT Wild et al.	
		FILING DATE March 16, 2001	GROUP 1646
U.S. PATENT DOCUMENTS			

EXAMINER INITIAL	DOCUMENT NUMBER	DATE	NAME	CLASS	SUB-CLASS	FILING DATE
AA						
AB						
AC						
AD						
AE						
AF						
AG						
AH						
AI						
AJ						
AK						

RECEIVED

APR 17 2002

TECH CENTER 1600/2900

FOREIGN PATENT DOCUMENTS						
EXAMINER INITIAL	DOCUMENT NUMBER	DATE	COUNTRY	CLASS	SUB-CLASS	TRANSLATION
AL						Yes No
AM						Yes No
AN						Yes No
AO						Yes No
AP						Yes No

## OTHER (Including Author, Title, Date, Pertinent Pages, etc.)

AT	13	Weng, Y., and Weiss, C.D., "Mutational Analysis of Residues in the Coiled-Coil Domain of Human Immunodeficiency Virus Type 1 Transmembrane Protein gp41," J. Virol. 72:9676-9682, American Society for Microbiology/DC (1998)		

EXAMINER	DATE CONSIDERED

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to Applicant.